Sanofi’s Lunsekimig Meets Goals in Asthma, Nasal Polyps Apr 7, 2026: Sanofi reported lunsekimig met primary endpoints in two registration-stage studies for severe asthma and nasal polyps (Investing.com), pressuring pipeline valuations.

Sanofi’s Lunsekimig Meets Goals in Asthma, Nasal Polyps: Apr 7, 2026: Sanofi reported lunsekimig met primary endpoints in two registration-stage studies for severe asthma and nasal polyps (Investing.com), pressuring… 👈 Read full analysis #Sanofi #Lunsekimig #Asthma #NasalPolyps #RespiratoryHealth